TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02487147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free Air Portable Air Powered Respirator
Description: The Free Air PAPR is a portable air powered respirator that you will wear like a backpack with a mask and tubing attached.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: N95 Respirator
Description: The N95 respirator is a mask that is standardly used clinically at Wake Forest Baptist Health.
Study: NCT02534883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: To be place vaginally
Study: NCT01458496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: The intervention will take approximately six months to complete. A combination of group and individual face-to-face meetings will be used. Participants will be divided into groups of 20 for group meetings. Groups will be brought together for a group coaching session at the beginning and the end of the coaching process (i.e., intervention). Each participant will also receive four individual coaching sessions with the health coach and will be able to avail of three one-hour telephone coaching sessions during the six month intervention. Participants will be encouraged to utilize telephone coaching for key support periods.
Study: NCT03976518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered on Day 1 every 21 days (+/- 3 days).
Study: NCT00530946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 2.5mg/Atorvastatin 10mg
Description: Single pill combination, dosed once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5mg/Atorvastatin 5mg
Description: Single pill combination, dosed once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5mg/Atorvastatin 10mg
Description: Single pill combination, dosed once daily for 8 weeks
Study: NCT01185756

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MIBG for diagnostic purpose
Description: All patients will undergo the diagnostic test specific to the study.
Study: NCT03177785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EverydayMatters
Study: NCT00789646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lidocaine/NSS
Description: First injection: subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival NSS 0.4 ml. before antibiotic injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NSS/Lidocaine
Description: First injection: subconjunctival NSS 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection
Study: NCT04628611

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video laryngoscopy
Description: Endotracheal intubation using video laryngoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible intubating laryngoscopy
Description: Endotracheal intubation using flexible intubating laryngoscope
Study: NCT04368897

Intervention type: DIAGNOSTIC_TEST
Intervention: CAG length <22
Description: CAG repeat length in exon 1 of AR gene

Intervention type: DIAGNOSTIC_TEST
Intervention: CAG length >=22
Description: CAG repeat length in exon 1 of AR gene
Study: NCT02534883

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To be placed vaginally
Study: NCT00437307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d
Study: NCT03933280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: i.v. nalbuphine bolus of 50 μg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: i.v. nalbuphine bolus of 50 μg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: A bolus i.v. dose of propofol 0.5 mg/kg followed by an infusion of 0.025 mg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: i.v. loading dose of dexmedetomidine 1 μg/kg over 10 min followed by a maintenance infusion of 0.5 μg/kg/h.
Study: NCT03870282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.
Study: NCT03870282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.
Study: NCT03933280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benoxinate Hydrochloride 0.4% Eye Drops
Description: Benoxinate hydrochloride 0.4% eye drops instilled twice, 5 minutes apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benoxinate Hydrochloride 0.4% Eye Drops
Description: Benoxinate hydrochloride 0.4% eye drops instilled twice, 5 minutes apart.
Study: NCT03714061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: The PNE will be administered following Explaining Pain concepts, initially contextualizing the importance of the program, addressing concepts of neuroscience and pain, incorrect information about what is pain, how the brain responds to nociception in a variety of situations, and how an experience of danger can trigger or aggravate a state of pain, coexistence of several potential protection systems, central sensitization and how to promote behavioral change, abandoning incorrect beliefs, proposing graded activity exposure.~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management Education
Description: Concepts about pain, musculoskeletal pain, chronic pain and disability will be addressed. Participants will be guided on the process of chronic pain, associated suffering, conceptual model of fear-avoidance and clarified on avoidant and confronting profiles. In a third phase, strategies will be presented on how to deal with chronic pain, with advice on the harmful effects of restricting activities and the use of drug therapy in a careful way (Dupeyron et al, 2011).~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises (reinforcement) and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks.
Study: NCT00052936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study: NCT03842774

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exract of Gelidium elegans
Description: Exract of Gelidium elegans will be given to the test group.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement will be given to the test group.
Study: NCT04171908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional Physical therapy for the upper limb

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: semi-inversive tech
Description: Conventional Physical therapy for the upper limb plus Semi-inversive tech
Study: NCT03870282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.
Study: NCT00005097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E and Placebo
Description: Areas of sun damaged skin with actinic keratoses to be treated will be mapped and photographed on patient's bilateral arms. One of the patient's arms will be assigned to be treated with topical Polyphenon E, the patient's other arm with placebo vehicle in a random, double blind manner. The patient's arm treatment areas will receive daily applications of a premeasured amount of drug or placebo. Patients will be seen every other week for 12 weeks to check for effects of the applications and monitor for compliance or possible side effects.
Study: NCT00996879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup, Oral, 5 mg, Single dose, 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Capsules, Oral, 300 mg, Every 12 hours, 8 days
Study: NCT01928290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT00052936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study: NCT01928290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Study: NCT01108211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Platform
Description: The patients receive treatment by standing on the Vibration Platform 20 minutes a day, five days a week. The platform will deliver a vibration of 0.3g with a vertical displacement of 0.085mm at 35 Hz.
Study: NCT00813631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: silver-releasing dressings
Description: Experimental group are accepted primary dressing the AQUACEL Ag. control group are provided with the AQUACEL on the wound surface. Wound specialist or primary nurses undertaking wound care are informed by inclusion criteria that the treatment shall be adhered to during the two-week study period.All wounds are cleansed with sterile saline prior to assessment and dressing application.The sterile, non-woven sodium carboxymethylcellulose primary AQUACEL Ag with 1.2% ionic silver.Each secondary dressing is covered a sterile gauze.Dressings are changed between daily assessments when judged necessary.Patients attended the wound ward weekly for treatment evaluation. All participating clinics used the same wound management guidelines and data collection forms.
Study: NCT01465620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hygienic-dietetic measures
Description: Therapeutic education about hygienic-dietetic measures followed by a 5 minutes phone call per week during 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hygienic-dietetic measures
Description: Therapeutic education about hygienic-dietetic measures followed by only one phone call
Study: NCT00831766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
Study: NCT02911714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason Contrast-Enhanced Ultrasound
Description: In both arms, we will use Lumason to measure kidney allograft perfusion via contrast-enhanced ultrasound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason Contrast-Enhanced Ultrasound
Description: In both arms, we will use Lumason to measure kidney allograft perfusion via contrast-enhanced ultrasound.
Study: NCT03571425

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: A placebo beverage will be consumed orally
Study: NCT00052936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen
Study: NCT00831766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
Study: NCT00052936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study: NCT00831766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide (Revlimid®)
Description: Lenalidomide as outlined in Phase I and Phase II Treatment Arms.
Study: NCT00052936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study: NCT00052936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study: NCT00679926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once daily
Description: Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
Study: NCT00052936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study: NCT03427502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: 10 ml of 0.5% bupivacaine with 1:2,00,000 adrenaline. For children less than 12 years of age, 0.25% bupivacaine with 1:2,00,000 adrenaline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline
Study: NCT02571166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV529
Description: Live, Replication-defective HSV-2 virus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: 500 mg orally, once daily for 4 weeks
Study: NCT01262742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 90mcg carbetocin, IV, over 1 minute following delivery of the fetal head.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 110mcg carbetocin, IV, over 1 minute following delivery of the fetal head.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 120mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
Study: NCT01819974

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stratified medication review
Description: A mediciation review will be performed in patients with high medication error rik. Patients in the highest risk will receive the medication review from a clinical pharmacologist whereas patients assessed in lesser risk will receive the medication review from a clinical pharmacist.
Study: NCT00866736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: 100mg QD
Study: NCT02060474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triac
Description: Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.
Study: NCT04007770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 10 treatments of acupuncture over the course of 10 weeks with a +/- 7 day window

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: 10 treatments of sham acupuncture over the course of 10 weeks with a +/- 7 day window. After the 16-week study concludes patients in this group will have the option of receiving up to 10 sessions of real acupuncture; however, these sessions must be completed within 6 months of study conclusion.
Study: NCT02340169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topicort® (desoximetasone) Topical Spray, 0.25%
Description: Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days
Study: NCT00496431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: histone deacetylase inhibitor (ITF2357)
Description: 50 mg b.i.d. (or every 8 hours or every 6 hours), every day
Study: NCT02569567

Intervention type: PROCEDURE
Intervention: Smart-Shear Wave(SSW) imaging
Description: 1. All Smart-Shear Wave(SSW) imaging examinations will be performed by one operator.~2. The right lobe of the liver is examined through the intercostal view with the patient lying in a supine or semi-decubitus position with the right arm in maximal abduction.~3. Once the optimal sizes of the regions of interest is chosen, they are fixed for subsequent measurement in each subject. Special attention is paid to avoid any focal lesion, vessels, biliary tracts, or artifacts from nearby lung gas or cardiac movement.

Intervention type: PROCEDURE
Intervention: Transient elastography(TE)
Description: 1. Using the M probe in patients with BMI \<30 kg/m2.~2. Liver measurement is taken at either the seventh or eighth intercostal space of each subject over the right lobe of the liver. The measuring depth ranges from 2.5 to 6.5 cm below the skin surface.~3. Examinations are performed by a sonographer blinded to S-shear wave elastography, and biological results.
Study: NCT02068677

Intervention type: OTHER
Group type: OTHER
Intervention: Sympathetic response
Description: Sympathetic response will be defined as change in heart rate by \>10 bpm and change in BP \<10mmHg.

Intervention type: OTHER
Group type: OTHER
Intervention: no sympathetic response
Description: no Sympathetic response will be defined as change in heart rate by \<10 bpm and change in BP \<10mmHg.
Study: NCT02725476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb5871
Study: NCT03088787

Intervention type: DEVICE
Intervention: Nexfin measuremtents
Description: There will be only observational recordings, no interevntion
Study: NCT00581399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NO-NUMO™ High Vacuum Body Cavity Drainage System
Description: (1) disposable NO-NUMO™ body cavity drainage tubes, (2) disposable Vario™ fluid management canisters and (3) Vario™ portable vacuum pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVC Chest Tube
Description: Standard PVC Chest Tube Sizes 14-36 French
Study: NCT00052936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT05272397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate 20 Mg Oral Tablet
Description: 20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart